Abstract
We retrospectively analyzed treatment patterns and healthcare costs among patients diagnosed with diffuse large B-cell lymphoma (DLBCL) during each line of therapy (LOT) using data from the IBM® MarketScan® Commercial and Medicare Supplemental Databases from January 2011 to May 2017. Patients were included if they had a diagnosis of DLBCL, ≥12 months of disease-free continuous enrollment prediagnosis, and ≥1 month of postdiagnosis follow-up. Of 2066 eligible patients receiving first-line treatment, 17% (n = 340) received second-line treatment; of these, 23% (n = 77) received third-line treatment. Mean healthcare expenditures (treatment duration) for first, second, and third LOTs were $111,314 (124.5 days), $88,472 (80.8 days), and $103,365 (70.9 days), respectively. When adjusted to 30-day period costs, first, second, and third LOT healthcare expenditures increased to $26,825, $32,857, and $43,854, respectively. Patients with newly diagnosed and relapsed/refractory DLBCL incur a significant cost burden (for payers), and such costs increase as patients proceed through subsequent LOTs.
Disclosure statement
JT, DM, and MB are employees of IBM Watson Health, which received funding from Juno Therapeutics, a Celgene company (before the acquisition of Celgene by Bristol-Myers Squibb), to execute this study.
JG is an employee of Juno Therapeutics, a Bristol-Myers Squibb company, and may own stock in Bristol-Myers Squibb.
MG and SS are employees of BluePath Solutions, which received funding from Juno Therapeutics, a Bristol-Myers Squibb company, to conduct the data analyses.
KCC was an employee of Juno Therapeutics, a Celgene company, at the time the analyses were conducted (before the acquisition of Celgene by Bristol-Myers Squibb) and may own stock in Bristol-Myers Squibb.
RTM has served as a consultant to Athersys, Inc., CRISPR Therapeutics, Incyte Corporation, Juno Therapeutics, Kite Pharma, and Novartis, and shares a patent with Athersys, Inc., managed by Oregon Health & Science University.
Data availability statement
Data requests may be submitted to Celgene at www.CelgeneClinicalDataSharing.com and must include a description of the research proposal.